Oral Breast Cancer Drug Wins Broader FDA Nod for ESR1-Mutated Disease

(MedPage Today) — The FDA approved the oral estrogen receptor antagonist imlunestrant (Inluriyo) for previously treated ESR1-mutated advanced/metastatic breast cancer, the agency announced Thursday.
The approval stipulates use in adults with…